Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study aim was to investigate the efficacy and safety of Osilodrostat in patients with Cushing's syndrome due to causes other than Cushing's disease in Japan.
This was a Phase II, single arm, open-label, dose titration, multi-center study which consisted of two distinct Study Periods plus an optional extension period in non-CD patients with CS. The 3 Study Periods (two distinct Study Periods plus an optional extension period) were as follows:
Study Period I [Week 0 (Day 1) to Week-12]: Study Period I was the dose titration period to achieve a stable therapeutic dose and to assess the efficacy and safety of osilodrostat.
The dosing regimen of osilodrostat in this study was titrated according to the following escalation sequence: osilodrostat 2 mg bid, 5 mg bid, 10 mg bid, 20 mg bid, and 30 mg bid. Dose adjustments were based on the serum cortisol values measured by the local lab at each site. Osilodrostat titration was done weekly for the initial 4-weeks, up to a maximum dose of 10 mg bid.
The mean of three 24-hour UFC (mUFC) values were measured to evaluate the efficacy in this period.
Study Period II (After Week-12 to Week-48): Study Period II was the period to assess the sustainability of efficacy and long term safety.
During Study Period II, only patients who tolerated and agreed to continue osilodrostat treatment continued on the study. The patient was administered with the stable therapeutic dose which was achieved in the Study Period I.
Optional extension period (After Week-48): Patients who continued to receive clinical benefit, as assessed by the study Investigator and who wished to enter the extension period were reconsented at Week-48. Patients who entered the extension period continued to be treated with the study drug without interruption to be assessed for efficacy and safety. Patients who continued to benefit from study treatment as assessed by the study investigator and who completed Week-72 were offered to participate in a separate long-term safety follow-up study. The optional extension period ended after all patients had completed Week-72 or had discontinued early.
Post-treatment Follow-up: All patients had 30 days safety follow-up after the last dose of study treatment.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Osilodrostat | Experimental | Patients in this arm took the study drug, osilodrostat. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Osilodrostat | Drug | Osirodrostat 1mg, 5mg & 10mg in the form of film-coated tablets was used for oral administration. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change in the Mean Urine Free Cortisol (mUFC) at the Individual Level at Week 12 | Percent change from baseline in the mUFC at the individual patient level | Baseline, 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change From Baseline in the mUFC at Individual Patient Level at Week 24 (Day 169) and Week 48 (Day 337) | Percent change from baseline in the mUFC at the individual patient level | Baseline, Week 24 (day 169) and Week 48 (day 337) |
| Absolute Change From Baseline in the mUFC at Week 12 (Day 85), Week 24 (Day 169) and Week 48 (Day 337) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | Fukushima | Fukushima | 960 1295 | Japan | ||
| Novartis Investigative Site |
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com
Not provided
Not provided
Not provided
Planned subjects: 10 subjects
Planned subjects: 10 subjects Actual enrolled: 9 subjects
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Osilodrostat | Patients in this arm took the study drug, osilodrostat. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Osilodrostat | Patients in this arm took the study drug, osilodrostat. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percent Change in the Mean Urine Free Cortisol (mUFC) at the Individual Level at Week 12 | Percent change from baseline in the mUFC at the individual patient level | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | percentage change | Baseline, 12 weeks |
|
|
Adverse events (AEs) were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of 68.0 weeks.
AE description; Any sign or symptom that occurs during the study treatment plus the 30 days post treatment
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Osilodrostat | Patients in this arm took the study drug, osilodrostat. | 0 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Myocardial infarction | Cardiac disorders | MedDRA (21.1) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Iron deficiency anaemia | Blood and lymphatic system disorders | MedDRA (21.1) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Novartis PharmaCeuticals | 862-778-8300 | novartis.email@novartis.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jul 31, 2018 | Oct 24, 2019 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jun 22, 2018 | Oct 24, 2019 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D003480 | Cushing Syndrome |
| D000182 | ACTH Syndrome, Ectopic |
| D000306 | Adrenal Cortex Neoplasms |
| C565662 | Acth-Independent Macronodular Adrenal Hyperplasia |
| ID | Term |
|---|---|
| D000308 | Adrenocortical Hyperfunction |
| D000307 | Adrenal Gland Diseases |
| D004700 | Endocrine System Diseases |
| D009384 | Paraneoplastic Endocrine Syndromes |
Not provided
Not provided
| ID | Term |
|---|---|
| C553306 | Osilodrostat |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Absolute change from baseline in the mUFC |
| Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Percentage Change From Baseline in the mUFC at Week 12 (Day 85), Week 24 (Day 169) and Week 48 (Day 337) | Percent change from baseline in the mUFC | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Percentage of Participants With mUFC Response of Complete, Partial, and Overall Response | Complete response rate = percentage of participants who had mUFC≤ ULN; Partial response rate = Percentage of participants who had mUFC>ULN and at least 50% reduction from baseline in mUFC. Overall response rate = Percentage of participants who had mUFC ≤ ULN or at least 50% reduction from baseline. | 12, 24 and 48 weeks |
| Absolute Change From Baseline in Morning Serum Cortisol at Individual Level | Absolute change from baseline in morning serum cortisol at the individual patient level | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Percentage Change From Baseline in Morning Serum Cortisol at Individual Level | Percentage change from baseline in morning serum cortisol at the individual patient level | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Absolute Change From Baseline in ACTH and Other Adrenal Steroid Hormones at Individual Level | Absolute change from baseline in several steroid hormones at individual levels: ACTH, Serum 11-deoxycorticosterone, Aldosterone, Estradiol | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Percentage Change From Baseline in ACTH and Other Adrenal Steroid Hormones at Individual Level | Percent change from baseline in several steroid hormones at individual levels: ACTH, Serum 11-deoxycorticosterone, Aldosterone, Estradiol | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Absolute Change From Baseline in Other Adrenal Steroid Hormones at Individual Levels | Absolute change from baseline in several steroid hormones at individual levels: Serum 11-deoxycortisol, Testosterone | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Percentage Change From Baseline in Other Adrenal Steroid Hormones at Individual Levels | Percent change from baseline in several steroid hormones at individual levels: Serum 11-deoxycortisol, Testosterone | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Fasting Glucose, at Individual Level | Absolute change in cardiovascular-related metabolic parameter fasting glucose, associated with Cushing's syndrome (CS) | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Fasting Glucose, at Individual Level | Percentasge change in cardiovascular-related metabolic parameter fasting glucose, associated with Cushing's syndrome (CS) | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, HbA1c, at Individual Level | Absolute change in cardiovascular-related metabolic parameter HbA1c associated with Cushing's syndrome (CS) | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, HbA1c, at Individual Level | Percentage change in cardiovascular-related metabolic parameter HbA1c associated with Cushing's syndrome (CS) | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Absolute Change From Baseline in Cardiovascular-related Metabolic Parameters, Cholesterol, HDL Cholesterol, LDL Cholesterol & Triglycerides, at Individual Level | Absolute change in cardiovascular-related metabolic parameters: cholesterol, HDL cholesterol, LDL cholesterol & triglycerides, associated with Cushing's syndrome (CS) | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Percentage Change From Baseline in Cardiovascular-related Metabolic Parameters, Cholesterol, HDL Cholesterol, LDL Cholesterol & Triglycerides, at Individual Level | Percent change in cardiovascular-related metabolic parameters: cholesterol, HDL cholesterol, LDL cholesterol & triglycerides, associated with Cushing's syndrome (CS) | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, BMI, at Individual Level | Absolute change in cardiovascular-related metabolic parameter: BMI, associated with Cushing's syndrome (CS) | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, BMI, at Individual Level | Percent change in cardiovascular-related metabolic parameter: BMI, associated with Cushing's syndrome (CS) | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Waist Circumference, at Individual Level | Absolute change in cardiovascular-related metabolic parameter: Waist circumference, associated with Cushing's syndrome (CS) | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Waist Circumference, at Individual Level | Percent change in cardiovascular-related metabolic parameter: Waist circumference, associated with Cushing's syndrome (CS) | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Sitting Blood Pressure (BP) at Individual Level | Absolute change in cardiovascular-related metabolic parameter: sitting systolic BP & sitting diastolic BP, associated with Cushing's syndrome (CS) | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Sitting Blood Pressure (BP) at Individual Level | Percentage change in cardiovascular-related metabolic parameter: sitting systolic BP & sitting diastolic BP, associated with Cushing's syndrome | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Total Scores in Patient-Reported Outcomes Health-related Quality of Life (QoL) as Assessed by Cushing QoL at Individual Level | The Cushing's Disease Health-Related Quality of Life Questionnaire (Cushing QoL) (version 1.0) was developed to evaluate quality of life in patients with Cushing's syndrome (Webb et al 2008). The Cushing QoL is comprised of 12 items that capture patient responses on seven concepts: daily activities, healing and pain, mood and self-confidence, social concerns, physical appearance, memory and concern about the future. Each questionnaire of the Cushing QOL has a scale of 1-5 where '1' corresponding to 'Always' or 'Very much' and '5' to 'Never' or 'Not at all'. The lower the score, the greater the impact on HRQoL. The score is the sum of all the item response and can range from 12 (worst) to 60 points (best). | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Total Scores in Patient-Reported Outcomes Health-related Quality of Life (QoL) as Assessed by Beck Depression Inventory II (BDI-ll) Depression Score at Individual Level | The Beck Depression Inventory II (BDI-II) is a patient reported instrument that consists of 21 items designed to assess the intensity of depression in clinical & normal patients in the preceding two weeks. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression. Each of 21 items corresponds to a symptom of depression and the sum of total score will be calculated where each item has a four-point scale ranging from 0 to 3, leading to a total score from zero to 63. | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
| Plasma Concentrations of Osilodrostat (LCI699) at Week 0 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Week 0 |
| Plasma Concentrations of Osilodrostat (LCI699) at Week 1 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Week 1, 2 hours post-dose |
| Plasma Concentrations of Osilodrostat (LCI699) at Week 2 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Week 2 |
| Plasma Concentrations of Osilodrostat (LCI699) at Week 3 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Week 3, 2 hours post-dose |
| Plasma Concentrations of Osilodrostat (LCI699) at Week 4 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Week 4, 2 hours post-dose |
| Plasma Concentrations of Osilodrostat (LCI699) at Week 6 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Week 6, 2 hours post-dose |
| Plasma Concentrations of Osilodrostat (LCI699) at Week 8 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Week 8, 2 hours post-dose |
| Plasma Concentrations of Osilodrostat (LCI699) at Week 10 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Week 10, 2 hours post-dose |
| Plasma Concentrations of Osilodrostat (LCI699) at Week 12 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Week 12 |
| Plasma Concentrations of Osilodrostat (LCI699) at Week 16 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Week 16, 2 hours post-dose |
| Plasma Concentrations of Osilodrostat (LCI699) at Week 20 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Week 20, 2 hours post-dose |
| Plasma Concentrations of Osilodrostat (LCI699) at Week 24 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Week 24, 2 hours post-dose |
| Yokohama |
| Kanagawa |
| 245-8575 |
| Japan |
| Novartis Investigative Site | Sendai | Miyagi | 980 8574 | Japan |
| Novartis Investigative Site | Chiba | 260 8677 | Japan |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Number | participants |
|
| Type of disease | Number | Participants |
|
|
| Secondary | Percent Change From Baseline in the mUFC at Individual Patient Level at Week 24 (Day 169) and Week 48 (Day 337) | Percent change from baseline in the mUFC at the individual patient level | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | percentage change | Baseline, Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Absolute Change From Baseline in the mUFC at Week 12 (Day 85), Week 24 (Day 169) and Week 48 (Day 337) | Absolute change from baseline in the mUFC | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Median | Full Range | nmol/24hr | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Percentage Change From Baseline in the mUFC at Week 12 (Day 85), Week 24 (Day 169) and Week 48 (Day 337) | Percent change from baseline in the mUFC | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Median | Full Range | percentage change | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Percentage of Participants With mUFC Response of Complete, Partial, and Overall Response | Complete response rate = percentage of participants who had mUFC≤ ULN; Partial response rate = Percentage of participants who had mUFC>ULN and at least 50% reduction from baseline in mUFC. Overall response rate = Percentage of participants who had mUFC ≤ ULN or at least 50% reduction from baseline. | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | 95% Confidence Interval | Percentage of participants | 12, 24 and 48 weeks |
|
|
|
| Secondary | Absolute Change From Baseline in Morning Serum Cortisol at Individual Level | Absolute change from baseline in morning serum cortisol at the individual patient level | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | nmol/L | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Percentage Change From Baseline in Morning Serum Cortisol at Individual Level | Percentage change from baseline in morning serum cortisol at the individual patient level | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | percentage change | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Absolute Change From Baseline in ACTH and Other Adrenal Steroid Hormones at Individual Level | Absolute change from baseline in several steroid hormones at individual levels: ACTH, Serum 11-deoxycorticosterone, Aldosterone, Estradiol | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | pmol/L | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Percentage Change From Baseline in ACTH and Other Adrenal Steroid Hormones at Individual Level | Percent change from baseline in several steroid hormones at individual levels: ACTH, Serum 11-deoxycorticosterone, Aldosterone, Estradiol | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | percentage change | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Absolute Change From Baseline in Other Adrenal Steroid Hormones at Individual Levels | Absolute change from baseline in several steroid hormones at individual levels: Serum 11-deoxycortisol, Testosterone | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | nmol/L | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Percentage Change From Baseline in Other Adrenal Steroid Hormones at Individual Levels | Percent change from baseline in several steroid hormones at individual levels: Serum 11-deoxycortisol, Testosterone | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | percentage change | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Fasting Glucose, at Individual Level | Absolute change in cardiovascular-related metabolic parameter fasting glucose, associated with Cushing's syndrome (CS) | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | mmol/L | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Fasting Glucose, at Individual Level | Percentasge change in cardiovascular-related metabolic parameter fasting glucose, associated with Cushing's syndrome (CS) | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | percentage change | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, HbA1c, at Individual Level | Absolute change in cardiovascular-related metabolic parameter HbA1c associated with Cushing's syndrome (CS) | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | percentage of HbA1c | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, HbA1c, at Individual Level | Percentage change in cardiovascular-related metabolic parameter HbA1c associated with Cushing's syndrome (CS) | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | percentage change | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Absolute Change From Baseline in Cardiovascular-related Metabolic Parameters, Cholesterol, HDL Cholesterol, LDL Cholesterol & Triglycerides, at Individual Level | Absolute change in cardiovascular-related metabolic parameters: cholesterol, HDL cholesterol, LDL cholesterol & triglycerides, associated with Cushing's syndrome (CS) | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | mmol/L | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Percentage Change From Baseline in Cardiovascular-related Metabolic Parameters, Cholesterol, HDL Cholesterol, LDL Cholesterol & Triglycerides, at Individual Level | Percent change in cardiovascular-related metabolic parameters: cholesterol, HDL cholesterol, LDL cholesterol & triglycerides, associated with Cushing's syndrome (CS) | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | percentage change | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, BMI, at Individual Level | Absolute change in cardiovascular-related metabolic parameter: BMI, associated with Cushing's syndrome (CS) | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | kg/m^2 | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, BMI, at Individual Level | Percent change in cardiovascular-related metabolic parameter: BMI, associated with Cushing's syndrome (CS) | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | percentage change | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Waist Circumference, at Individual Level | Absolute change in cardiovascular-related metabolic parameter: Waist circumference, associated with Cushing's syndrome (CS) | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | cm | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Waist Circumference, at Individual Level | Percent change in cardiovascular-related metabolic parameter: Waist circumference, associated with Cushing's syndrome (CS) | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | percentage change | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Sitting Blood Pressure (BP) at Individual Level | Absolute change in cardiovascular-related metabolic parameter: sitting systolic BP & sitting diastolic BP, associated with Cushing's syndrome (CS) | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | mmHg | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Sitting Blood Pressure (BP) at Individual Level | Percentage change in cardiovascular-related metabolic parameter: sitting systolic BP & sitting diastolic BP, associated with Cushing's syndrome | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | percentage change | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Total Scores in Patient-Reported Outcomes Health-related Quality of Life (QoL) as Assessed by Cushing QoL at Individual Level | The Cushing's Disease Health-Related Quality of Life Questionnaire (Cushing QoL) (version 1.0) was developed to evaluate quality of life in patients with Cushing's syndrome (Webb et al 2008). The Cushing QoL is comprised of 12 items that capture patient responses on seven concepts: daily activities, healing and pain, mood and self-confidence, social concerns, physical appearance, memory and concern about the future. Each questionnaire of the Cushing QOL has a scale of 1-5 where '1' corresponding to 'Always' or 'Very much' and '5' to 'Never' or 'Not at all'. The lower the score, the greater the impact on HRQoL. The score is the sum of all the item response and can range from 12 (worst) to 60 points (best). | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | scores on a scale | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Total Scores in Patient-Reported Outcomes Health-related Quality of Life (QoL) as Assessed by Beck Depression Inventory II (BDI-ll) Depression Score at Individual Level | The Beck Depression Inventory II (BDI-II) is a patient reported instrument that consists of 21 items designed to assess the intensity of depression in clinical & normal patients in the preceding two weeks. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression. Each of 21 items corresponds to a symptom of depression and the sum of total score will be calculated where each item has a four-point scale ranging from 0 to 3, leading to a total score from zero to 63. | Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat. | Posted | Number | scores on a scale | Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337) |
|
|
|
| Secondary | Plasma Concentrations of Osilodrostat (LCI699) at Week 0 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Pharmacokinetic analysis set (PAS): Consisted of all patients who received at least one dose of osilodrostat and had at least one evaluable PK concentration at any visit (post-first-dose). | Posted | Mean | Standard Deviation | ng/mL | Week 0 |
|
|
|
| Secondary | Plasma Concentrations of Osilodrostat (LCI699) at Week 1 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Pharmacokinetic analysis set (PAS): Consisted of all patients who received at least one dose of osilodrostat and had at least one evaluable PK concentration at any visit (post-first-dose). | Posted | Mean | Standard Deviation | ng/mL | Week 1, 2 hours post-dose |
|
|
|
| Secondary | Plasma Concentrations of Osilodrostat (LCI699) at Week 2 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Pharmacokinetic analysis set (PAS): Consisted of all patients who received at least one dose of osilodrostat and had at least one evaluable PK concentration at any visit (post-first-dose). | Posted | Mean | Standard Deviation | ng/mL | Week 2 |
|
|
|
| Secondary | Plasma Concentrations of Osilodrostat (LCI699) at Week 3 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Pharmacokinetic analysis set (PAS): Consisted of all patients who received at least one dose of osilodrostat and had at least one evaluable PK concentration at any visit (post-first-dose). | Posted | Mean | Standard Deviation | ng/mL | Week 3, 2 hours post-dose |
|
|
|
| Secondary | Plasma Concentrations of Osilodrostat (LCI699) at Week 4 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Pharmacokinetic analysis set (PAS): Consisted of all patients who received at least one dose of osilodrostat and had at least one evaluable PK concentration at any visit (post-first-dose). | Posted | Mean | Standard Deviation | ng/mL | Week 4, 2 hours post-dose |
|
|
|
| Secondary | Plasma Concentrations of Osilodrostat (LCI699) at Week 6 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Pharmacokinetic analysis set (PAS): Consisted of all patients who received at least one dose of osilodrostat and had at least one evaluable PK concentration at any visit (post-first-dose). | Posted | Mean | Standard Deviation | ng/mL | Week 6, 2 hours post-dose |
|
|
|
| Secondary | Plasma Concentrations of Osilodrostat (LCI699) at Week 8 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Pharmacokinetic analysis set (PAS): Consisted of all patients who received at least one dose of osilodrostat and had at least one evaluable PK concentration at any visit (post-first-dose). | Posted | Mean | Standard Deviation | ng/mL | Week 8, 2 hours post-dose |
|
|
|
| Secondary | Plasma Concentrations of Osilodrostat (LCI699) at Week 10 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Pharmacokinetic analysis set (PAS): Consisted of all patients who received at least one dose of osilodrostat and had at least one evaluable PK concentration at any visit (post-first-dose). | Posted | Mean | Standard Deviation | ng/mL | Week 10, 2 hours post-dose |
|
|
|
| Secondary | Plasma Concentrations of Osilodrostat (LCI699) at Week 12 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Pharmacokinetic analysis set (PAS): Consisted of all patients who received at least one dose of osilodrostat and had at least one evaluable PK concentration at any visit (post-first-dose). | Posted | Mean | Standard Deviation | ng/mL | Week 12 |
|
|
|
| Secondary | Plasma Concentrations of Osilodrostat (LCI699) at Week 16 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Pharmacokinetic analysis set (PAS): Consisted of all patients who received at least one dose of osilodrostat and had at least one evaluable PK concentration at any visit (post-first-dose). | Posted | Mean | Standard Deviation | ng/mL | Week 16, 2 hours post-dose |
|
|
|
| Secondary | Plasma Concentrations of Osilodrostat (LCI699) at Week 20 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Pharmacokinetic analysis set (PAS): Consisted of all patients who received at least one dose of osilodrostat and had at least one evaluable PK concentration at any visit (post-first-dose). | Posted | Mean | Standard Deviation | ng/mL | Week 20, 2 hours post-dose |
|
|
|
| Secondary | Plasma Concentrations of Osilodrostat (LCI699) at Week 24 | Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window. | Pharmacokinetic analysis set (PAS): Consisted of all patients who received at least one dose of osilodrostat and had at least one evaluable PK concentration at any visit (post-first-dose). | Posted | Mean | Standard Deviation | ng/mL | Week 24, 2 hours post-dose |
|
|
|
| 9 |
| 4 |
| 9 |
| 9 |
| 9 |
| Adrenal insufficiency | Endocrine disorders | MedDRA (21.1) | Systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA (21.1) | Systematic Assessment |
|
| Psychiatric symptom | Psychiatric disorders | MedDRA (21.1) | Systematic Assessment |
|
| Vertigo | Ear and labyrinth disorders | MedDRA (21.1) | Systematic Assessment |
|
| Adrenal insufficiency | Endocrine disorders | MedDRA (21.1) | Systematic Assessment |
|
| Steroid withdrawal syndrome | Endocrine disorders | MedDRA (21.1) | Systematic Assessment |
|
| Abdominal distension | Gastrointestinal disorders | MedDRA (21.1) | Systematic Assessment |
|
| Abdominal pain upper | Gastrointestinal disorders | MedDRA (21.1) | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA (21.1) | Systematic Assessment |
|
| Dental caries | Gastrointestinal disorders | MedDRA (21.1) | Systematic Assessment |
|
| Enterocolitis | Gastrointestinal disorders | MedDRA (21.1) | Systematic Assessment |
|
| Stomatitis | Gastrointestinal disorders | MedDRA (21.1) | Systematic Assessment |
|
| Malaise | General disorders | MedDRA (21.1) | Systematic Assessment |
|
| Oedema peripheral | General disorders | MedDRA (21.1) | Systematic Assessment |
|
| Pyrexia | General disorders | MedDRA (21.1) | Systematic Assessment |
|
| Primary biliary cholangitis | Hepatobiliary disorders | MedDRA (21.1) | Systematic Assessment |
|
| Cellulitis | Infections and infestations | MedDRA (21.1) | Systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA (21.1) | Systematic Assessment |
|
| Osteomyelitis | Infections and infestations | MedDRA (21.1) | Systematic Assessment |
|
| Rib fracture | Injury, poisoning and procedural complications | MedDRA (21.1) | Systematic Assessment |
|
| Alanine aminotransferase increased | Investigations | MedDRA (21.1) | Systematic Assessment |
|
| Amylase increased | Investigations | MedDRA (21.1) | Systematic Assessment |
|
| Aspartate aminotransferase increased | Investigations | MedDRA (21.1) | Systematic Assessment |
|
| Blood alkaline phosphatase increased | Investigations | MedDRA (21.1) | Systematic Assessment |
|
| Gamma-glutamyltransferase increased | Investigations | MedDRA (21.1) | Systematic Assessment |
|
| Weight decreased | Investigations | MedDRA (21.1) | Systematic Assessment |
|
| Weight increased | Investigations | MedDRA (21.1) | Systematic Assessment |
|
| Decreased appetite | Metabolism and nutrition disorders | MedDRA (21.1) | Systematic Assessment |
|
| Dyslipidaemia | Metabolism and nutrition disorders | MedDRA (21.1) | Systematic Assessment |
|
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA (21.1) | Systematic Assessment |
|
| Hypomagnesaemia | Metabolism and nutrition disorders | MedDRA (21.1) | Systematic Assessment |
|
| Increased appetite | Metabolism and nutrition disorders | MedDRA (21.1) | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA (21.1) | Systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA (21.1) | Systematic Assessment |
|
| Anxiety | Psychiatric disorders | MedDRA (21.1) | Systematic Assessment |
|
| Insomnia | Psychiatric disorders | MedDRA (21.1) | Systematic Assessment |
|
| Mood altered | Psychiatric disorders | MedDRA (21.1) | Systematic Assessment |
|
| Nightmare | Psychiatric disorders | MedDRA (21.1) | Systematic Assessment |
|
| Reactive psychosis | Psychiatric disorders | MedDRA (21.1) | Systematic Assessment |
|
| Alopecia | Skin and subcutaneous tissue disorders | MedDRA (21.1) | Systematic Assessment |
|
| Dermal cyst | Skin and subcutaneous tissue disorders | MedDRA (21.1) | Systematic Assessment |
|
| Dermatitis acneiform | Skin and subcutaneous tissue disorders | MedDRA (21.1) | Systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA (21.1) | Systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA (21.1) | Systematic Assessment |
|
| Peripheral coldness | Vascular disorders | MedDRA (21.1) | Systematic Assessment |
|
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety
| D010257 | Paraneoplastic Syndromes |
| D009369 | Neoplasms |
| D000310 | Adrenal Gland Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D000303 | Adrenal Cortex Diseases |
|
| Adrenal adenoma-Patient 1: Wk 24(n=0) |
|
| Adrenal adenoma-Patient 1: Wk 48(n=0) |
|
| Adrenal adenoma-Patient 2: Wk 24(n=1) |
|
|
| Adrenal adenoma-Patient 2: Wk 48(n=0) |
|
| Adrenal adenoma-Patient 3: Wk 24(n=0) |
|
| Adrenal adenoma-Patient 3: Wk 48(n=0) |
|
| Adrenal adenoma-Patient 4: Wk 24(n=0) |
|
| Adrenal adenoma-Patient 4: Wk 48(n=0) |
|
| Adrenal adenoma-Patient 5: Wk 24(n=0) |
|
| Adrenal adenoma-Patient 5: Wk 48(n=0) |
|
| Ectopic corticotropin syndrome-Pt 1: Wk 24(n=1) |
|
|
| Ectopic corticotropin syndrome-Pt 1: Wk 48(n=1) |
|
|
| Ectopic corticotropin syndrome-Pt 2: Wk 24(n=0) |
|
| Ectopic corticotropin syndrome-Pt 2: Wk 48(n=0) |
|
| Ectopic corticotropin syndrome-Pt 3: Wk 24(n=0) |
|
| Ectopic corticotropin syndrome-Pt 3: Wk 48(n=0) |
|
|
| Week 48 (day 337) (n = 2) |
|
|
|
| Week 48 (day 337) (n = 2) |
|
|
|
| Week 12: Overall responders |
|
|
| Week 24: Complete responders (n =3) |
|
|
| Week 24: Partial responders (n = 3) |
|
|
| Week 24: Overall responders (n = 3) |
|
|
| Week 48: Complete responders (n = 2) |
|
|
| Week 48: Partial responders (n = 2) |
|
|
| Week 48: Overall responders (n = 2) |
|
|
|
| AIMAH-Patient 1: Wk 48 (n = 1) |
|
|
| Adrenal adenoma-Patient 1: Wk 12 (n =1) |
|
|
| Adrenal adenoma-Patient 1:Wk 24 (n =0) |
|
| Adrenal adenoma-Patient 1: Wk 48 (n =0) |
|
| Adrenal adenoma-Patient 2: Wk 12(n =1) |
|
|
| Adrenal adenoma-Patient 2: Wk 24 (n =1) |
|
|
| Adrenal adenoma-Patient 2: Wk 48 (n =0) |
|
| Adrenal adenoma-Patient 3: Wk 12 (n =1) |
|
|
| Adrenal adenoma-Patient 3: Wk 24 (n =0) |
|
| Adrenal adenoma-Patient 3: Wk 48 (n =0) |
|
| Adrenal adenoma-Patient 4: Wk 12 (n =1) |
|
|
| Adrenal adenoma-Patient 4: Wk 24 (n =0) |
|
| Adrenal adenoma-Patient 4: Wk 48 (n =0) |
|
| Adrenal adenoma-Patient 5: Wk 12 (n =1) |
|
|
| Adrenal adenoma-Patient 5: Wk 24 (n =0) |
|
| Adrenal adenoma-Patient 5: Wk 48 (n =0) |
|
| Ectopic corticotropin syndrome-Pt 1: Wk 12 (n =1) |
|
|
| Ectopic corticotropin syndrome-Pt 1: Wk24 (n=1) |
|
|
| Ectopic corticotropin syndrome-Pt 1: Wk48 (n=1) |
|
|
| Ectopic corticotropin syndrome-Pt 2: Wk 12 (n =0) |
|
| Ectopic corticotropin syndrome-Pt 2: Wk 24 (n=0) |
|
| Ectopic corticotropin syndrome-Pt 2: Wk48 (n=0) |
|
| Ectopic corticotropin syndrome-Pt 3: Wk 12 (n =0) |
|
| Ectopic corticotropin syndrome-Pt 3: Wk24 (n=0) |
|
| Ectopic corticotropin syndrome-Pt 3: Wk48 (n=0) |
|
|
| AIMAH-Patient 1: Wk 48 (n = 1) |
|
|
| Adrenal adenoma-Patient 1: Wk 12 (n =1) |
|
|
| Adrenal adenoma-Patient 1:Wk 24 (n =0) |
|
| Adrenal adenoma-Patient 1: Wk 48 (n =0) |
|
| Adrenal adenoma-Patient 2: Wk 12(n =1) |
|
|
| Adrenal adenoma-Patient 2: Wk 24 (n =1) |
|
|
| Adrenal adenoma-Patient 2: Wk 48 (n =0) |
|
| Adrenal adenoma-Patient 3: Wk 12 (n =1) |
|
|
| Adrenal adenoma-Patient 3: Wk 24 (n =0) |
|
| Adrenal adenoma-Patient 3: Wk 48 (n =0) |
|
| Adrenal adenoma-Patient 4: Wk 12 (n =1) |
|
|
| Adrenal adenoma-Patient 4: Wk 24 (n =0) |
|
| Adrenal adenoma-Patient 4: Wk 48 (n =0) |
|
| Adrenal adenoma-Patient 5: Wk 12 (n =1) |
|
|
| Adrenal adenoma-Patient 5: Wk 24 (n =0) |
|
| Adrenal adenoma-Patient 5: Wk 48 (n =0) |
|
| Ectopic corticotropin syndrome-Pt 1: Wk 12 (n =1) |
|
|
| Ectopic corticotropin syndrome-Pt 1: Wk24 (n=1) |
|
|
| Ectopic corticotropin syndrome-Pt 1: Wk48 (n=1) |
|
|
| Ectopic corticotropin syndrome-Pt 2: Wk 12 (n =0) |
|
| Ectopic corticotropin syndrome-Pt 2: Wk24 (n=0) |
|
| Ectopic corticotropin syndrome-Pt 2: Wk48 (n=0) |
|
| Ectopic corticotropin syndrome-Pt 3: Wk 12 (n =0) |
|
| Ectopic corticotropin syndrome-Pt 3: Wk24 (n=0) |
|
| Ectopic corticotropin syndrome-Pt 3: Wk48 (n=0) |
|
|
| AIMAH-Pt 1 Wk 24 (n=1,1,1,1) |
|
|
| AIMAH-Pt 1 Wk 48 (n=1,1,1,1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n=1,1,1,1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n=0,0,0,0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n=1,1,1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24(n=1,1,1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n=0,0,0,0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n=1,1,1,1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n=0, 0,0,0) |
|
| Adrenal adenoma-Pt 3 Wk 48(n=0,0,0,0) |
|
| Adrenal adenoma-Pt 4 Wk 12 (n=1,1,1,1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n=0,0,0,0) |
|
| Adrenal adenoma-Pt 4 Wk 48 (n=0,0,0,0) |
|
| Adrenal adenoma-Pt 5 Wk 12 (n=1,1,1,1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n=0,0,0,0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n=0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 1: Wk 12 (n=1,1,1,1) |
|
|
| Ectopic ACTH syndrome-Pt 1: Wk 24 (n=1,1,1,1) |
|
|
| Ectopic ACTH syndrome-Pt 1: Wk 48 (n=1,1,1,1) |
|
|
| Ectopic ACTH syndrome-Pt 2: Wk 12 (n=0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 2: Wk 24 (n=0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 2: Wk 48 (n=0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 3: Wk 12 (n=0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 3: Wk 24 (n=0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 3: Wk 48 (n=0,0,0,0) |
|
|
| AIMAH-Pt 1 Wk 24 (n=0,1,0,1) |
|
|
| AIMAH-Pt 1 Wk 48 (n=0,1,0,1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n =0,0,1,1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n =0,0,1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24 (n =0,0,1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n =0,0,0, 0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n =0,0,1,1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 3 Wk 48 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 4 Wk 12 (n =0,0,1,1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 4 Wk 48 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 5 Wk 12 (n =0,0,0,1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n =0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 1: Wk 12 (n=1,1,0,1) |
|
|
| Ectopic ACTH syndrome-Pt 1: Wk 24 (n=1,1,0,1) |
|
|
| Ectopic ACTH syndrome-Pt 1: Wk 48 (n=1,1,0,1) |
|
|
| Ectopic ACTH syndrome-Pt 2: Wk 12 (n=0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 24 (n =0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 48 (n =0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 12 (n =0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 24 (n =0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 48 (n =0,0,0,0) |
|
| AIMAH-Pt 1 Wk 24 (n = 1,1) |
|
|
| AIMAH-Pt 1 Wk 48 (n = 1,1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n = 1,1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n =0,0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n =0,0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n = 1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24 (n = 1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n = 0,0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n = 1,1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n = 0, 0) |
|
| Adrenal adenoma-Pt 3 Wk 48 (n =0,0) |
|
| Adrenal adenoma-Pt 4 Wk 12 (n = 1,1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n = 0,0) |
|
| Adrenal adenoma-Pt 4 Wk 48 (n = 0,0) |
|
| Adrenal adenoma-Pt 5 Wk 12 (n = 1,1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n =0,0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n = 0,0) |
|
| Ectopic ACTH syndrome-Pt 1 Wk 12(n = 1,1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n = 1,1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n = 1,1) |
|
|
| Ectopic ACTH syndrome-Pt 2 Wk 12 (n = 0,0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 24 (n = 0,0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 48 (n = 0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 12(n =0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 24 (n = 0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 48(n = 0,0) |
|
| AIMAH-Pt 1 Wk 24 (n=1, 1) |
|
|
| AIMAH-Pt 1 Wk 48 (n=1, 1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n=1,1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n=0,0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n=0,0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n=1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24 (n=1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n=0,0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n=1, 1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n=0,0) |
|
| Adrenal adenoma-Pt 3 Wk 48 (n=0,0 |
|
| Adrenal adenoma-Pt 4 Wk 12 (n=1, 1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n=0,0 |
|
| Adrenal adenoma-Pt 4 Wk 48 (n=0,0 |
|
| Adrenal adenoma-Pt 5 Wk 12 (n=1,1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n=0,0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 1 Wk 12 (n=1, 1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1, 1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1, 1) |
|
|
| Ectopic ACTH syndrome-Pt 2 Wk 12 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 24 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 48 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 12(n=0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 24 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 48 (n=0,0) |
|
|
| AIMAH-Patient (Pt) 1 Wk 48 (n =1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24 (n =1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 3 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 4 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 4 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 5 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n =0) |
|
| Ectopic ACTH syndrome-Pt 1 Wk 12 (n =1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1) |
|
|
| Ectopic ACTH syndrome-Pt 2 Wk 12 (n=0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 24 (n =0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 48 (n =0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 12 (n=0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 24 (n =0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 48 (n =0) |
|
|
| AIMAH-Patient (Pt) 1 Wk 48 (n =1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24 (n =1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 3 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 4 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 4 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 5 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n =0) |
|
| Ectopic ACTH syndrome-Pt 1 Wk 12 (n =1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1) |
|
|
| Ectopic ACTH syndrome-Pt 2 Wk 12 (n=0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 24 (n =0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 48 (n =0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 12 (n=0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 24 (n =0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 48 (n =0) |
|
|
| AIMAH-Pt 1 Wk 48 (n=1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24 (n=1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 3 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 4 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 4 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 5 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n=0) |
|
| Ectopic ACTH syndrome-Pt 1 Wk 12 (n=1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1) |
|
|
| Ectopic ACTH syndrome-Pt 2 Wk 12(n=0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 24 (n=0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 48 (n=0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 12(n=0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 24 (n=0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 48 (n=0) |
|
|
| AIMAH-Pt 1 Wk 48 (n=1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24 (n=1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 3 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 4 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 4 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 5 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n=0) |
|
| Ectopic ACTH syndrome-Pt 1 Wk 12 (n=1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1) |
|
|
| Ectopic ACTH syndrome-Pt 2 Wk 12(n=0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 24 (n=0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 48 (n=0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 12(n=0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 24 (n=0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 48 (n=0) |
|
|
| AIMAH-Pt 1 Wk 24 (n =1,1,1,1) |
|
|
| AIMAH-Pt 1 Wk 48 (n =1,1,1,1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n =1,1,1,1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n =1,1,1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24 (n =1,1,1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n =1,1,1,1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 3 Wk 48 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 4 Wk 12 (n =1,1,1,1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt Wk 48 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 5 Wk 12 (n =1,1,1,1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n =0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 1 Wk 12(n =1,1,1,1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1,1,1,1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1,1,1,1) |
|
|
| Ectopic ACTH syndrome-Pt 2 Wk 12 (n =0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 24 (n =0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 48 (n =0,0,0,0,) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 12 (n =0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 24 (n =0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 48 (n =0,0,0,0) |
|
|
| AIMAH-Pt 1 Wk 24 (n =1,1,1,1) |
|
|
| AIMAH-Pt 1 Wk 48 (n =1,1,1,1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n =1,1,1,1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n =1,1,1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24 (n =1,1,1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n =1,1,1,1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 3 Wk 48 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 4 Wk 12 (n =1,1,1,1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 4 Wk 48 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 5 Wk 12 (n =1,1,1,1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n =0,0,0,0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n =0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 1 Wk 12(n =1,1,1,1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1,1,1,1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1,1,1,1) |
|
|
| Ectopic ACTH syndrome-Pt 2 Wk 12 (n =0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 24 (n =0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 48 (n =0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 12 (n =0,0,0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 48 (n =0,0,0,0) |
|
|
| AIMAH-Pt 1 Wk 48 (n =1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24 (n =1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 3 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 4 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 4 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 5 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n =0) |
|
| Ectopic ACTH syndrome-Pt 1 Wk 12(n =1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1) |
|
|
| Ectopic ACTH syndrome-Pt 2 Wk 12(n =0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 24 (n =0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 48 (n =0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 12 (n =0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 24 (n =0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 48 (n =0) |
|
|
| AIMAH-Pt 1 Wk 48 (n =1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24 (n =1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 3 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 4 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 4 Wk 48 (n =0) |
|
| Adrenal adenoma-Pt 5 Wk 12 (n =1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n =0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n =0) |
|
| Ectopic ACTH syndrome-Pt 1 Wk 12(n =1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1) |
|
|
| Ectopic ACTH syndrome-Pt 2 Wk 12(n =0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 24 (n =0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 48 (n =0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 12 (n =0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 24 (n =0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 48 (n =0) |
|
|
| AIMAH-Pt1 Wk 48 (n=1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24 (n=1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 3 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 4 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 4 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 5 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n=0) |
|
| Ectopic ACTH syndrome-Pt 1 Wk 12 (n=1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1) |
|
|
| Ectopic ACTH syndrome-Pt 2 Wk 12 (n=0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 24 (n=0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 48 (n=0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 12(n=0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 24 (n=0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 48 (n=0) |
|
|
| AIMAH-Pt1 Wk 48 (n=1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24 (n=1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 3 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 4 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 4 Wk 48 (n=0) |
|
| Adrenal adenoma-Pt 5 Wk 12 (n=1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n=0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n=0) |
|
| Ectopic ACTH syndrome-Pt 1 Wk 12 (n=1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1) |
|
|
| Ectopic ACTH syndrome-Pt 2 Wk 12 (n=0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 24 (n=0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 48 (n=0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 12(n=0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 24 (n=0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 48 (n=0) |
|
| AIMAH-Patient (Pt) 1 Wk 24 (n =1, 1) |
|
|
| AIMAH-Patient (Pt) 1 Wk 48 (n =1, 1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n=1,1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n=0,0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n=0,0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n=1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24 (n=1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n=0,0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n=1,1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n=0,0) |
|
| Adrenal adenoma-Pt 3 Wk 48 (n=0,0) |
|
| Adrenal adenoma-Pt 4 Wk 12 (n=1,1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n=0,0) |
|
| Adrenal adenoma-Pt 4 Wk 48 (n=0,0) |
|
| Adrenal adenoma-Pt 5 Wk 12 (n=1,1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n=0,0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 1 Wk 12(n=1,1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1,1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1,1) |
|
|
| Ectopic ACTH syndrome-Pt 2 Wk 12 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 24 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 48 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 12 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 24 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 48 (n=0,0) |
|
| AIMAH-Patient (Pt) 1 Wk 24 (n =1, 1) |
|
|
| AIMAH-Patient (Pt) 1 Wk 48 (n =1, 1) |
|
|
| Adrenal adenoma-Pt 1 Wk 12 (n=1,1) |
|
|
| Adrenal adenoma-Pt 1 Wk 24 (n=0,0) |
|
| Adrenal adenoma-Pt 1 Wk 48 (n=0,0) |
|
| Adrenal adenoma-Pt 2 Wk 12 (n=1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 24 (n=1,1) |
|
|
| Adrenal adenoma-Pt 2 Wk 48 (n=0,0) |
|
| Adrenal adenoma-Pt 3 Wk 12 (n=1,1) |
|
|
| Adrenal adenoma-Pt 3 Wk 24 (n=0,0) |
|
| Adrenal adenoma-Pt 3 Wk 48 (n=0,0) |
|
| Adrenal adenoma-Pt 4 Wk 12 (n=1,1) |
|
|
| Adrenal adenoma-Pt 4 Wk 24 (n=0,0) |
|
| Adrenal adenoma-Pt 4 Wk 48 (n=0,0) |
|
| Adrenal adenoma-Pt 5 Wk 12 (n=1,1) |
|
|
| Adrenal adenoma-Pt 5 Wk 24 (n=0,0) |
|
| Adrenal adenoma-Pt 5 Wk 48 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 1 Wk 12(n=1,1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1,1) |
|
|
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1,1) |
|
|
| Ectopic ACTH syndrome-Pt 2 Wk 12 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 24 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 2 Wk 48 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 12 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 24 (n=0,0) |
|
| Ectopic ACTH syndrome-Pt 3 Wk 48 (n=0,0) |
|
|
| AIMAH-Patient 1: Wk 48 (n=1) |
|
|
| Adrenal adenoma-Patient 1: Wk 12(n=1) |
|
|
| Adrenal adenoma-Patient 1: Wk 24 (n = 0) |
|
| Adrenal adenoma-Patient 1: Wk 48 (n = 0) |
|
| Adrenal adenoma-Patient 2: Wk 12(n=1) |
|
|
| Adrenal adenoma-Patient 2: Wk 24 (n = 1) |
|
|
| Adrenal adenoma-Patient 2: Wk 48 (n =0) |
|
| Adrenal adenoma-Patient 3: Wk 12 (n =1) |
|
|
| Adrenal adenoma-Patient 3: Wk 24 (n = 0) |
|
| Adrenal adenoma-Patient 3: Wk 48 (n = 0) |
|
| Adrenal adenoma-Patient 4: Wk 12 (n =1) |
|
|
| Adrenal adenoma-Patient 4: Wk 24 (n = 0) |
|
| Adrenal adenoma-Patient 4: Wk 48 (n = 0) |
|
| Adrenal adenoma-Patient 5: Wk 12 (n=1) |
|
|
| Adrenal adenoma-Patient 5: Wk 24 (n = 0) |
|
| Adrenal adenoma-Patient 5: Wk 48 (n = 0) |
|
| Ectopic corticotropin syndrome-Pt 1: Wk 12 (n =1) |
|
|
| Ectopic corticotropin syndrome-Pt 1: Wk 24 (n =1) |
|
|
| Ectopic corticotropin syndrome-Pt 1: Wk 48 (n =1) |
|
|
| Ectopic corticotropin syndrome-Pt 2: Wk 12 (n =0) |
|
| Ectopic corticotropin syndrome-Pt 2: Wk 24 (n =0) |
|
| Ectopic corticotropin syndrome-Pt 2: Wk 48 (n =0) |
|
| Ectopic corticotropin syndrome-Pt 3: Wk 12 n =0) |
|
| Ectopic corticotropin syndrome-Pt 3: Wk 24 (n =0) |
|
| Ectopic corticotropin syndrome-Pt 3: Wk 48 (n =0) |
|
|
| AIMAH-Patient 1: Wk 48 (n =1) |
|
|
| Adrenal adenoma-Patient 1: Wk 12 (n =1) |
|
|
| Adrenal adenoma-Patient 1: Wk 24 (n = 0) |
|
| Adrenal adenoma-Patient 1: Wk 48 (n = 0) |
|
| Adrenal adenoma-Patient 2: Wk 12 (n =1) |
|
|
| Adrenal adenoma-Patient 2: Wk 24 (n =1) |
|
|
| Adrenal adenoma-Patient 2: Wk 48 (n = 0) |
|
| Adrenal adenoma-Patient 3: Wk 12 (n =1) |
|
|
| Adrenal adenoma-Patient 3: Wk 24 (n = 0) |
|
| Adrenal adenoma-Patient 3: Wk 48 (n = 0) |
|
| Adrenal adenoma-Patient 4: Wk 12 (n =1) |
|
|
| Adrenal adenoma-Patient 4: Wk 24 (n = 0) |
|
| Adrenal adenoma-Patient 4: Wk 48 (n = 0) |
|
| Adrenal adenoma-Patient 5: Wk 12 (n =1) |
|
|
| Adrenal adenoma-Patient 5: Wk 24 (n = 0) |
|
| Adrenal adenoma-Patient 5: Wk 48 (n = 0) |
|
| Ectopic corticotropin syndrome-Pt 1: Wk 12 (n =1) |
|
|
| Ectopic corticotropin syndrome-Pt 1: Wk 24 (n =1) |
|
|
| Ectopic corticotropin syndrome-Pt 1: Wk 48 (n =1) |
|
|
| Ectopic corticotropin syndrome-Pt 2: Wk 12 (n =0) |
|
| Ectopic corticotropin syndrome-Pt 2: Wk 24 (n =0) |
|
| Ectopic corticotropin syndrome-Pt 2: Wk 48 (n =0) |
|
| Ectopic corticotropin syndrome-Pt 3: Wk 12 (n =0) |
|
| Ectopic corticotropin syndrome-Pt 3: Wk 24 (n =0) |
|
| Ectopic corticotropin syndrome-Pt 3: Wk 48 (n =0) |
|
| Week 0: 4 hours post-dose |
|
|
| Week 2: 2 hours post-dose |
|
|
| Week 2: 4 hours post-dose |
|
|
| Week 12: 4 hours post-dose |
|